Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Groupe Francophone des Myelodysplasies Identifier:
First received: February 25, 2011
Last updated: October 28, 2015
Last verified: April 2015

Patients will receive escalating doses of ldarubicin combined to Azacitidine given at the FDA/EMEA approved Schedule and dosing.

For the Phase I study :

Determine the safety and tolerance of escalating doses of Idarubicin combined to Azacitidine in patients with INT-2 or higher risk MDS.

For the phase II study:

Primary: Evaluate rate and duration of response (according to IWG 2006 criteria and IWG 2000 criteria) to the combination of Idarubicin and Azacitidine in patients with INT-2 or higher risk MDS

Condition Intervention Phase
High Grade Myelodysplastic Syndrome Lesions
Drug: azacitidine and idarubicin
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I-II Study of the Efficacy and Safety of Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes

Resource links provided by NLM:

Further study details as provided by Groupe Francophone des Myelodysplasies:

Primary Outcome Measures:
  • To determined tolerance and dose limiting toxicities to idarubicin and azacitidine association. [ Time Frame: After 12 weeks treatment ]

Secondary Outcome Measures:
  • to determined overall response rate and response duration [ Time Frame: After six months ]

Estimated Enrollment: 41
Study Start Date: December 2010
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: azacitidine 75mg/m²/d + idarubicin 5mg/m²/d

phase I : palier 1 have 10 patients and palier 2 have to 10 patients.

palier 1: Ida 5mg/m²/d (D8) + AZACITIDINE 75mg/m²/d (D1-D7)

Drug: azacitidine and idarubicin
azacitidine:100mg, 75mg/m²/d, during 7days every 28 days (D1-D7). Idarubicin: 5mg/ml, 5mg/m²/d (palier1) or 10mg/m²/d (palier2), D8
Experimental: Azacitidine 75mg/m²/d + idarubicin 10mg/m²/d
palier 2: Ida 10mg/m²/d (D8)+ Azacitidine 75mg/m²/d (D1-D7)
Drug: azacitidine and idarubicin
azacitidine:100mg, 75mg/m²/d, during 7days every 28 days (D1-D7). Idarubicin: 5mg/ml, 5mg/m²/d (palier1) or 10mg/m²/d (palier2), D8

Detailed Description:

Patients will receive ldarubicin combined to Azacitidine.

  • The first 10 patients will receive Idarubicin 5 mg/m2/d on day 8 of each cycle of Azacitidine 75 mg/m2/d CI during 7 days (First Cohort ).
  • Progression or not to the next cohort of 10 patients : Idarubicin 10 mgm2/d on day 8 of each cycle of Azacitidine 75 mg/m2/d CI during 7 days (Second cohort of 10 patients), will be decided after completion of the first cohort, after review of hematological toxicity by an independent safety review committee (SRC).
  • The next 21 patients will be treated either according to the first or second cohort schedule of Idarubicin, after review of hematological toxicity and efficacy by an independent safety review committee (SRC).

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Documented diagnosis of MDS, or CMML with WBC < 13,000/mm3 that meets IPSS criteria for intermediate-2 or high-risk disease,
  • IPSS score ≥1.5
  • Myocardial function do not contraindicate the use of idarubicin
  • Age ≥ 18 years
  • Performance Status ≤2 according to ECOG.
  • Serum creatinine < 1.5 x ULN and normal levels of electrolytes (serum sodium 136-145 mmol/l, Potassium 3,5-4,5 mmol/l, alkaline Reserve 23-29 mmol/l, , Calcium 2,15-2,5 mmol/l, Phosphore 0,87-1,45 mmol/l) Serum aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or alanine transaminase (ALT)/serum glutamate pyruvate transaminase (SGPT) < 1.5 x upper limit of normal (ULN)
  • Serum total bilirubin < 1.5 x ULN.
  • Must be able to adhere to the study visit schedule and other protocol requirements
  • Signed informed consent.

Female subjects of childbearing potential must:

• Accept effective contraception without interruption throughout the duration of study and up to three months after the end of treatment.

Male subjects must

  • Agree to use condoms throughout study drug therapy, during any dose interruption and for one week after cessation of study therapy and up to three months after the final treatment if their partner is of childbearing potential and has no contraception.
  • Agree to learn the procedures for preservation of sperm

Exclusion Criteria:

  • Uncontrolled infection
  • Prior therapy with anthracycline for MDS.
  • Eligible for an allogeneic stem cell transplantation.
  • Prior therapy with demethylating agents within the last 3 months
  • Prior therapy with Hematopoietic growth factor (ESA or G-CSF) agents or cytotoxic agents (oral chemotherapy, low doses AraC) within the last 30 days.
  • Prior history of malignancy other than MDS (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast)
  • Pregnant or lactating females
  • Known HIV-1 positivity
  • Contra-indication to Anthracyclines
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01305135

Service des maladies du sang
CHU d'Angers, Angers, France, 49033
Service d'Hématologie Clinique
CHRU Clemenceau, Caen, France, 14033
Service d'Hématologie Clinique
CHU Albert Michallon, Grenoble, France, 38043
Service d'Hématologie Clinique
CHU de Limoges, Limoges, France, 87042
Département d'hématologie
Institut Paoli-Calmette, Marseille, France, 13009
Service d'Hématologie Clinique
CHU NICE, Hôpital l'Archet, Nice, France, 06202
Département d'hématologie
Centre Henri Becquerel, Rouen, France, 76038
Service d'Hématologie Clinique
Hôpital PURPAN, Toulouse, France, 31059
CHU d'Amiens
Amiens, France, 80054
CHU d'Angers
Angers, France, 49033
Hôpital de la cote basque
Bayonne, France, 64100
Hôpital Avicenne
Bobigny, France, 93009
CHU de Haut-Lévèque
Bordeaux Pessac, France, 33604
CHU Estaing
Clermont-Ferrand, France, 63000
CHU Dijon Hôpital d'enfants
Dijon, France, 21000
CH Le Mans
Le Mans, France, 72000
Centre Hospitalier Lyon Sud
Lyon, France, 69495
CHU Brabois
Nancy, France, 54511
CHU Hote dieu
Nantes, France, 44093
Hôpital saint louis
Paris, France, 75010
Hôpital Saint Antoine
Paris, France, 75012
Hôpital cochin
Paris, France, 75014
Centre hospitalier Joffre
Perpignan, France, 66046
CHU de Poitiers
Poitiers, France, 86021
CH de Périgueux
Périgueux, France, 24019
Hôpital Pontchaillou
Rennes, France, 35033
Hôpital Hautepierre
Strasbourg, France, 67098
Hôpital Purpan
Toulouse, France, 31059
Hôpital Bretonneau
Tours, France, 37000
CH de Valence
Valence, France, 26953
Institut Gustave Roussy
Villejuif, France, 94805
Hôpital Aziza Othmana
Tunis, Tunisia
Sponsors and Collaborators
Groupe Francophone des Myelodysplasies
Principal Investigator: Lionel ADES, PHD,MD GFM: Groupe Francophone des Myélodysplasies
  More Information

Responsible Party: Groupe Francophone des Myelodysplasies Identifier: NCT01305135     History of Changes
Other Study ID Numbers: GFM-AZA-IDA-09
Study First Received: February 25, 2011
Last Updated: October 28, 2015

Keywords provided by Groupe Francophone des Myelodysplasies:
myelodysplastic syndrome, azacitidine, idarubicin

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors processed this record on April 26, 2017